M.D., Executive Co-Director, Health Policy Research Institute, University of California, Irvine
Dr. Greenfield is the Executive Co-Director of the Health Policy Research Institute at the UC Irvine and Donald Bren Professor of Medicine. He and his colleagues have opened at least 4 new fields: nurse practitioners, outcomes research, patient participation in Medical Care, and heterogeneity of treatment effects. His accomplishments lie in the areas of quality of care assessment, enlarging patient’s role in care, clinical practice guidelines and comparative effectiveness research. He is a member of the National Academy of Medicine (NAM) and has been Chair or Co-Chair of 4 NAM committees: Guidance for the National Healthcare Disparities report; Cancer Survivors: Lost in Transition; Initial Priorities for Comparative Effectiveness Research; Clinical Practice Guidelines We Can Trust; and was a member of numerous prior NAM committees. He is Principal Investigator of the grant “Precision Medicine for Early Prostate Cancer: Integrating Biological and Patient Complexity Variables to Predict Treatment Response”.
Session Abstract – PMWC 2019 Silicon Valley
Session Synopsis: Precision oncology adoption into the clinical oncology workflow has been slow despite the technical and scientific advancements in molecular diagnostics and targeted therapeutics. Precision oncology incorporates in-depth genomic analysis of the patient’s tumor, interpretation of genomics results by the molecular tumor board (MTB), translation of findings into actionable therapeutic approaches, as well as navigation of the insurance and payor landscape in support of patients and providers. This session includes participants from various cancer centers that will share their learnings and the resulting added value to their institutions and medical communities, as well as the challenges they have to overcome when applying precision oncology through the MTB process.